Proposition - PharmXpert Academy

More documents

Recommendations

Info

The Korean Pharmaceutical Company List 401 24. Hawonpharm 1. Company Information Company Hawonpharm Representative kooh dae ho E-mail - Representative Phone No. Hompage Address Research Institute Address Year of Establishment The Number of Employees (06‘) 82-2-554-2012 www.hawonpharm.co.kr Representative Fax No. 82-2-554-4557 788-1 Yeoksam-dong, Kangnam-Gu, Seoul, 135-080, Korea 543-3 Gagokri, Jinwi-myeon, Pyeongtaek-si, Kyunggi-Do, Korea 1981 Sales (‘06) 37 Million$ Total The Number of 147 Researcher (‘06) 14 Total Contact Person yu sung jong Contact Phone 82-2-554-2012 Contact E-mail webmater@hawonpharm.co.kr Contact Fax 82-2-554-4557 Introduction of Company Hawon Pharmaceutical established a KGMP factory in 1994 to manufacture medical products of the finest quality. Since company was founded in May. 1981 we have been producing fine medical products of more than 100 items including Tablet, Capsule, Injection, solution&Gel, Including Cephalosporins. All our products are made under the high-quality manufacturing control standards. With introduction of automatic systems such as KGMP facility. Since we were approved as a BGMP in 2003 that enabled us to produce raw material drugs at our company, we have been producing excellent raw material drugs and other products that are differentiated from other pharmaceutical firms. We also conduct research with KIST(Korea Institute of Science and Technology) to making every effort to develop the excellent pharmaceuticals such as 3rd generation Cephem and Zidovudine. We are putting the best efforts to raise our competitiveness, thus we achieved the target turnover Of KRW 37 billion $. (2006 year) With a total of 8 branch office force that make up the distribution channels located in different regions of the country,
402 2007 Korea Pharmaceutical Industry Directory 2. Main Products Information No. 1 2 3 4 5 Classification ·Process improvement Process improvement Process improvement Process improvement Process improvement Section (Bio, Synthesis) synthesis synthesis The Name of Products Fazidone inj. Hawon Ceftriaxone Inj. Main Ingredient Cefazedone sodium Ceftriaxone Na Use (Indications) Cephalosporin Antibiotic Cephalosporin Antibiotic synthesis Ciploxacin Inj. Ciprofloxacin Quinolone Antibiotic synthesis Hawon Cefotaxime Inj. Cefotaxime Na Cephalosporin Antibiotic Formulation The Date of Sales inj. 2003 inj. 2000 inj. 2005 inj. 2000 synthesis Raben Tab. Alibendol digestive po 2003 6 - - Remist Tab. Rebamipide Antiulcer agent po 2004 7 - - Coxicam Cap. Meloxicam NSAIDs po 2004 8 - - Sporatin Tab. Acetyl-lcarnitin HCl Cerebral activator po 2004 9 - - FRONAN cap. Fluconazole Antifungals po 2006 Expected Exporting Countries USA, JPN, Europe, Southeast Asia... USA, JPN, Europe, Southeast Asia... USA, JPN, Europe, Southeast Asia... USA, JPN, Europe, Southeast Asia... USA, JPN, Europe, Southeast Asia... USA, JPN, Europe, Southeast Asia... USA, JPN, Europe, Southeast Asia... USA, JPN, Europe, Southeast Asia... USA, JPN, Europe, Southeast Asia... Etc. 3. R&D Figures No Classification Section (Bio, Synthesis) The Name of Technology Main Ingredient Use (Indications) The Duration of Development The Stage of Development Future Plan Expected Licencing (Domestic, Oversea) 1 Process improvement Herb medicine Efficient seperation of Harpagide from Devil's claw Harpagoside Harpagide Arthritis, Rheumatic disease 1 year search efficacy test
Page 2 and 3:
2007 Korea Pharmaceutical Industry
Page 4 and 5:
2007 Korea Pharmaceutical Industry
Page 6 and 7:
27. ILYANG PHARM ·········
Page 8 and 9:
Chapter 1. Outline of The Project 2
Page 10 and 11:
Chapter 1. Outline of The Project 2
Page 12 and 13:
Chapter 2. Pharmaceutical Industry
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
The Annex
Page 38 and 39:
316 2007 Korea Pharmaceutical Indus
Page 40 and 41:
The Korean Pharmaceutical Company L
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73: 4. Company Map The Korean Pharmace
Page 74 and 75: The Korean Pharmaceutical Company L
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
4. Company Map The Korean Pharmace
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
show all

Proposition - PharmXpert Academy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?